# US 2026/0060962 A1 · Methods and agents that stimulate mitochondrial turnover for treating disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060962 A1
- Document ID: US20260060962A1
- Status: Published application
- Kind: A1
- Application number: 19/212,461
- Filed: 2025-05-19
- Published: 2026-03-05
- Earliest claimed: 2021-01-28
- Assignees: Capacity Bio, Inc.
- Applicants: Capacity Bio, Inc.
- Inventors: Amy E. Wang; Alejandro Martorell-Riera; Kevin John Gaffney
- Web page: https://patentgrep.com/patent/US20260060962A1

## CPC

- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 38/085: {Angiotensins}
- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of stimulating mitophagy in a subject in need thereof administering to the subject a mitophagy-stimulating amount of a MAS receptor agonist or substance that triggers endogenous production of a MAS receptor agonist. The present disclosure also relates to medical intervention methods and agents, namely methods and agents for stimulation of mitochondrial turnover for treatment of disease in a mammal. The disclosure comprises a method of stimulating increased mitochondrial turnover in a mammal comprising administering to the mammal a pharmacologically suitable dose of a MAS receptor agonist; MAS receptor modulator; a substance that triggers endogenous production of a MAS receptor agonist; a substance that triggers endogenous production of a MAS receptor modulator; or any combination thereof. The pharmacological activity acting on MAS receptor in turn stimulates an increase in mitochondrial turnover in host cells, alleviating a disease state in the host mammalian organism.

## Claims

### Claim 1

A method for treating a disease or condition in a subject in need thereof comprising stimulating mitophagy in the subject by administering to the subject a mitophagy-stimulating amount of a MAS receptor agonist or substance that triggers endogenous production of a MAS receptor agonist, wherein the disease or condition is:
Sjorgen's syndrome, progeria, Rett Syndrome, Down Syndrome; ataxia-telangiectasia; autosomal dominant optic atrophy; Barth syndrome; Charcot-Marie-Tooth disease; Charlevoix-Saguenay spastic ataxia; Cockayne syndrome; Danon disease; Fabry disease; Fanconi anemia; Friedrich's ataxia; Fuchs endothelial dystrophy; Gaucher disease; intellectual developmental disorder with short stature and variable skeletal anomalies; Kearns-Sayre syndrome; Krabbe disease; lactic acidosis; Lafora disease; Leber's hereditary optic neuropathy (LHON); Leigh syndrome; mental retardation, X-linked, syndromic, Turner type (MRXST); maternally inherited diabetes and deafness syndrome (MIDD); microcephaly 18 (MCPH18); microphthalmia syndromic 7; mitochondrial DNA depletion syndromes (MDDS); mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS); mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); mitochondrial recessive ataxia syndrome (MIRAS); mtDNA heteroplasmy; methylmalonic acidemia (MMA); mucolipidosis II (ML II); multiple sulfatase deficiency; neurodegeneration with ataxia, dystonia, and gaze palsy (NADGP); myoclonus epilepsy with ragged red fibers (MERRF); neurodegeneration with brain iron accumulation 5 (NBIA5); neurodevelopment disorder with spastic quadriplegia and brain abnormalities with or without seizures (NEDSBAS); neuronal ceroid lipofuscinosis; Niemann-Pick disease; neuropathy, ataxia, and retinitis pigmentosa (NARP); Pearson syndrome; Pompe disease; rhabdomyosarcoma; schizophrenia; spastic paraplegia type 15; spastic paraplegia type 49; spinocerebellar ataxia 4 (SCA4); spinocerebellar ataxia 25 (SCA25); Vici syndrome; Werner syndrome; Wolfram syndrome; xeroderma pigmentosum (XP) group A; Zellweger syndrome; or any combination thereof.

### Claim 2

(canceled)

### Claim 3

A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising stimulating mitophagy in the subject by administering to the subject a mitophagy-stimulating amount of a MAS receptor agonist or substance that triggers endogenous production of a MAS receptor agonist;
wherein the subject exhibits a C9orf72 mutation, Optn (optineurin) mutation, or TBK1 mutation.

### Claim 4

A method for treating Parkinson's Disease in a subject in need thereof comprising stimulating mitophagy in the subject by administering to the subject a mitophagy-stimulating amount of a MAS receptor agonist or substance that triggers endogenous production of a MAS receptor agonist;
wherein the subject exhibits a LRRK2 mutation, GBA mutation, Pink1 mutation, or Prkn2 mutation.

### Claim at position 5

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering to the subject an effective amount of an agent that stimulates mitochondrial biogenesis.

### Claim at position 7

-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a human patient.

### Claim 13 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist is selected from the group consisting of:
a heterocyclic non-peptidic angiotensin(1-7) mimetic or analogue thereof;
angiotensin(1-7) or an analogue thereof;
Nle3-A(1-7) or an analogue thereof;
a 1-(p-thienylbenzyl)imidazole analogue; and
20-hydroxyecdysone or an analogue thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist is selected from the group consisting of:
Compound 7;
Compound 10;
Nle3-A(1-7);
angiotensin(1-7);
the Ang-1-6-Ser-O-glycosylated analogue of angiotensin(1-7); and
5-formyl-4-methoxy-2-phenyl-1-[[4-[2-(ethylaminocarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]imidazole.

### Claim 15 (depends on 14)

The method of claim 14, wherein the MAS receptor agonist is selected from the group consisting of
Compound 7;
Compound 10;
Nle3-A(1-7); and
angiotensin(1-7).

### Claim 16 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist is a compound of Formula (I):
in which:
R(1) is
(1) halogen;
(2) hydroxyl;
(3) (C1-C4)-alkoxy;
(4) (C1-C8)-alkoxy, wherein 1 to 6 carbon atoms are replaced by the heteroatoms O, S, or NH,
(5) (C1-C4)-alkoxy, substituted by a saturated cyclic ether;
(6) O—(C1-C4)-alkenyl;
(7) O—(C1-C4)-alkylaryl; or
(8) phenoxy, unsubstituted or substituted by a substituent selected from halogen, (C1-C3)-alkyl, (C1-C3)-alkoxy, and trifluoromethyl;
R(2) is
(1) CHO;
R(3) is
(1) (C1-C4)-alkyl; or
(2) aryl;
R(4) is
(1) hydrogen;
(2) halogen; or
(3) (C1-C4)-alkyl;
X is
(1) oxygen; or
(2) sulfur;
Y is
(1) oxygen; or
(2) NH;
R(5) is
(1) hydrogen;
(2) (C1-C6)-alkyl; or
(3) (C1-C4)-alkylaryl;
where R(5) can only be hydrogen if Y has the meaning mentioned under (2); and
R(6) is
(1) (C1-C8)-alkyl;
in any stereoisomeric form or mixture thereof in any ratio, or a physiologically acceptable salt thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist is a compound of Formula (II):
in which:
R(1) is chosen from among
1. (C1-C5)-alkyl, unsubstituted or substituted by a radical chosen from among NH2, halogen, O—(C1-C3)-alkyl, CO—O—(C1-C3)-alkyl and CO2H;
2. (C3-C8)-cycloalkyl;
3. (C1-C3)-alkyl-(C3-C8)-cycloalkyl;
4. (C6-C10)-aryl, unsubstituted or substituted by a radical chosen from halogen and O—(C1-C3)-alkyl;
5. (C1-C3)-alkyl-(C6-C10)-aryl, where the aryl radical is unsubstituted or substituted by a radical chosen from halogen and O—(C1-C3)-alkyl;
6. (C3-C5)-heteroaryl; and
7. (C1-C3)-alkyl-(C1-C5)-heteroaryl;
R(2) is chosen from among
1. hydrogen;
2. (C1-C6)-alkyl, unsubstituted or substituted by a radical chosen from halogen and O(C1-C3)-alkyl;
3. (C3-C8)-cycloalkyl;
4. (C1-C3)-alkyl-(C3-C8)-cycloalkyl;
5. (C6-C10)-aryl, unsubstituted or substituted by a radical chosen from among halogen, O—(C1-C3)-alkyl and CO—O—(C1-C3)-alkyl; and
6. (C1-C3)-alkyl-(C6-C10)-aryl, unsubstituted or substituted by a radical chosen from halogen and O(C1-C3)-alkyl;
R(3) is chosen from among
1. hydrogen;
2. COOH; and
3. COO—(C1-C4)-alkyl;
R(4) is chosen from among
1. hydrogen;
2. halogen; and
3. (C1-C4)-alkyl;
R(5) is chosen from
1. hydrogen, and
2. (C1-C6)-alkyl;
R(6) is chosen from among
1. hydrogen;
2. (C1-C6)-alkyl;
3. (C1-C3)-alkyl-(C3-C8)-cycloalkyl; and
4. (C2-C6)-alkenyl;
X is chosen from
1. oxygen, and
2. NH;
in all the stereoisomeric forms thereof, and mixtures thereof in all ratios, and the physiologically tolerated salts thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist comprises a compound of formula (III):
wherein:
ring A is a five-membered or six-membered heteroaryl or heterocyclyl ring containing either a combination of two non-adjacent nitrogen or oxygen atoms, or a combination of three or four nitrogen or oxygen atoms;
ring B is a five-membered or six-membered heteroaryl ring that contains at least one nitrogen atom;
ring C is an optionally substituted aryl ring;
A1, A2, A3, A4 are independently selected from a group consisting of ═N—, —C(═O)—, —C(Ra)═, ═C(Rb)—, —C(Rc)(Rd)—N(Re)—, —C(Rc)(Rd)—O—,
or —[C(Rc)(Rd)]n— with n being 1 or 2;
X1—X2 is (R6)C—N, N—C(R6), N—N, N—O, O—N, N—S or S—N;
X3 is (R7)C═C(R8), O, S, or N(R);
Z is O, NH or a bond to R5;
Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, hydroxyalkyl, alkoxyalkyl, alkoxy, aryloxy, formyl, acyl, acylamido or carboxy, provided that Ra and Rb can also join to form a ring of up to 6 atoms;
Rc and Rd are independently selected from a group consisting of hydrogen, alkyl, aryl, or heteroaryl, provided that Rc and Rd can also join to form a ring of up to 6 atoms;
Re is hydrogen, alkyl, aryl, heteroaryl, acyl, alkoxyacyl, aminoacyl, dialkylaminoacyl, or dialkylaminoacyl;
R1, R3, R4, R6, R7, and R8 are independently selected from a group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylmethyl, heteroarylmethyl, fluoro, bromo, iodo, cyano, hydroxy, amino, alkylamino, alkoxy, aryloxy, alkoxyalkyl, or aryloxyalkyl;
R2 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylmethyl, heteroarylmethyl, alkoxy, trifluoromethoxy, perfluoroalkoxy, aryloxy, alkoxyalkyl, or aryloxyalkyl;
R5 is alkyl, aryl, heteroaryl, hydroxyalkyl, carboxyalkyl, alkoxyalkyl, or aryloxyalkyl; and
R9 is hydrogen, alkyl, aryl, heteroaryl, acyl, alkoxyacyl, aminoacyl, dialkylaminoacyl, or dialkylaminoacyl. or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist comprises a sequence consisting of at least three contiguous amino acids of groups R1-R8 in the sequence of general formula (i) R1-R2-R3-R4-R5-R6-R7-R8
in which R1 and R2 together form a group of formula
X—RA—RB,
wherein X is H or a one to three peptide group
RA is selected from Asp, Glu, Asn, Acpc, Ala, Me2Gly, Pro, Bet, Glu(NH2), Gly, Asp(NH2), Suc, and glycosylated forms thereof;
RB is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg, D-Lys, His, and glycosylated forms thereof;
R3 is selected from the group consisting of Val, Ala, Leu, Nle, Ile, Gly, Pro, Aib, Acpc, Lys, Tyr, and glycosylated forms thereof;
R4 is selected from the group consisting of Tyr, Tyr(PO3)2, Thr, Ser, Hse, Ala, azaTyr; Tyr, Phe, and glycosylated forms thereof
R5 is selected from the group consisting of Ile, Ala, Leu, Nle, Val, Gly, and glycosylated forms thereof;
R6 is His, Arg, 6-NH2-Phe, Lys, and glycosylated forms thereof;
R7 is Pro, Ala, Gly, Ser, and glycosylated forms thereof; and
R8 is selected from the group consisting of Phe, Phe(Br), Ile, Tyr, Ser, Thr, Hyp, and glycosylated forms thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist is a sequence of the general formula (ii) Ala1-R2-R3-R4-R5-R6-R7 wherein
R2 is selected from Arg, Lys, Ala, Cit, Orn, Ser(Ac), Sar, D-Arg, and D-Lys;
R3 is selected from the group consisting of Val, Ala, Leu, Nle, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;
R4 is Ser, or forms a cyclic thioether with R7;
R5 is selected from the group consisting of Ile, Ala, Leu, Nle, Val, and Gly;
R6 is His, Arg, 6-NH2-Phe, Lys, and glycosylated forms thereof; and
R7 is Cys or forms a cyclic thioether with R4.

### Claim 21 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist is a compound of formula (IV):
wherein
V-U is a single carbon-carbon bond and Y is a hydroxyl group or a hydrogen, or V—U is a
C═C ethylene bond; X is an oxygen, Q is a carbonyl group;
R1 is chosen from: a group (C1-C6)W(C1-C6); a group (C1-C6)W(C1-C6)W(C1-C6); a group (C1-C6)W(C1-C6)CO2(C1-C6); a group (C1-C6)A, A representing a heterocycle optionally substituted by a group of the type OH, OMe, (C1-C6), N(C1-C6), CO2(C1-C6); a CH2Br group;
W being a heteroatom chosen from N, O and S.

### Claim 22 (depends on 1)

The method of claim 1, wherein the substance that triggers endogenous production of a MAS receptor agonist is a substance that triggers endogenous production of angiotensin(1-7).

### Claim at position 19

-26. (canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein the MAS receptor agonist or substance that triggers endogenous production of a MAS receptor agonist is administered as a pharmaceutical composition.

### Claim at position 21

-29. (canceled)
